Trial seeks cheaper alternative for rare disease patients
NCT ID NCT05843916
Summary
This study tested if a new, potentially more affordable version of an existing Fabry disease drug works as well and is as safe. It involved 20 adult patients who were already stable on the standard treatment, Fabrazyme. For one year, researchers monitored if switching them to the new drug, AGA BETA BS, kept their disease under control by checking blood markers, pain levels, and heart and kidney health.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for FABRY DISEASE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Centro Médico Santa María de la Salud
San Isidro, Buenos Aires, 1642, Argentina
-
Centro Oncológico Riojano Integral
La Rioja, F5300, Argentina
-
Clínica Universitaria Reina Fabiola
Córdoba, X5004, Argentina
-
Instituto de Investigaciones Clínicas Quilmes
Buenos Aires, Argentina
-
Instituto de Nefrología Pergamino S.R.L
Pergamino, Buenos Aires, 2700, Argentina
Conditions
Explore the condition pages connected to this study.